Biotechnology Healthcare - July/August 2008 - (Page 44)

full-cost benchmarking program. 2004. «http://ibiweb.org/do/ viewdocument/DocumentDetail? linkId=37837&aId=D732E93E74089 7CD25C644489EB118BF». Accessed July 16, 2008. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004;31: 849–855. Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization health and work performance questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46: S23–S37. Kessler RC, Stang PE, eds. Health and Work Productivity: Making the Business Case for Quality Health Care. The John D. and Catherine T. MacArthur Foundation Series on Mental Health and Development. Chicago: University of Chicago Press. 2006. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 suppl 1):1–12. Lee P. The economic impact of musculoskeletal disorders. Qual Life Res. 1994;(3 suppl 1):S85–S91. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care. 2006;44:304–310. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998;13(1 Pt 1):1–7. Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics. 2001; 19:917–925. Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22:165–184. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004; 50:1051–1065. MedPanel Inc. MedPanel survey of managed care medical directors predicts small rate of increase in MCO medical costs, reveals cost control strategies for 2006. May 2006. «http:// mcfpanelintelligence.com/view_ pr.asp?file=may092006». Accessed July16, 2008. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419. Merkesdal S, Ruof J, Schöffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 2001;44:528–534. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48: 2750–2762. Mullins CD, DeVries AR, Hsu VD, et al. Variability and growth in spending for outpatient specialty pharmaceuticals. Health Aff (Millwood). 2005;24: 1117–1127. Pavlovic M, Girardin E, Kapetanovic L, et al. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res. 2008;69:14–21. Pharmaceutical Care Management Association. Specialty pharmacy trends and management strategies. April 2006. «http://www.pcmanet.org/assets/ 2008-03-25_Research_sp_trends strategies.pdf». Accessed July 16, 2008. Prasad M, Wahlqvist P, Shikiar R, Shih Y. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics. 2004;22:225–244. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29: 305–320. Ranke MB. New preparations comprising recombinant human growth hormone: Deliberations on the issue of biosimilars. Horm Res. 2008;69:22–28. Regent Atlantic Capital LLC, Fiduciary Network. The continuing evolution of the pharmaceutical industry: Career challenges and opportunities. December 2007. «http://www. regentatlantic.com/media/pdf/ RegentAtlantic-Pharma-Paper-Dec07.pdf». Accessed July 16, 2008. Rosenthal MB, Landon BE, Normand SL, et al. Employers’ use of value-based purchasing strategies. JAMA. 2007;298:2281–2288. Ruof J, Hülsemann JL, Mittendorf T, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources. Ann Rheum Dis. 2003;62: 544–550. Schultz AB, Edington DW. Employee health and presenteeism: a systematic review. J Occup Rehabil. 2007;17: 547–579. Soderlin MK, Kautiainen H, Jonsson D, et al. The costs of early inflammatory joint disease: a population-based study in southern Sweden. Scand J Rheumatol. 2003;32:216–224. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999;26: 1681–1685. St. Clair EW, Van Der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–3443. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443–2454. Verstappen SM, Bijlsma JW, Verkleij H, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum. 2004;51:488–497. Walgreens Specialty Pharmacy. Walgreens specialty pharmacy outlook: State of the industry report-2007. Walgreens Co.; 2007;SP5751-0507. «http:// www.walgreenshealth.com/common/ pdf/FinalSOI05152007.pdf». Accessed July 16, 2008. Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol. 2007; 19:91–96. Yelin E. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates. J Rheumatol Suppl. 1996; 44:47–51. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:3046–3054. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis. 2002;61:335–340. Zhang J. Drug benefit fueled Medicare spending. The Wall Street Journal Online. Jan. 8, 2008:A2. «http://online.wsj.com/public/article/ SB119976460147574133.html?mod =blog». Accessed July 16, 2008. Disclosure Paresh Chaudhari, PharmD, MPH, reports that he has no financial arrangements or affiliations with manufacturers or products mentioned in this article. 44 BIOTECHNOLOGY HEALTHCARE · JULY/AUGUST 2008 http://ibiweb.org/do/viewdocument/DocumentDetail?linkId=37837&aId=D732E93E740897CD25C644489EB118BF http://ibiweb.org/do/viewdocument/DocumentDetail?linkId=37837&aId=D732E93E740897CD25C644489EB118BF http://ibiweb.org/do/viewdocument/DocumentDetail?linkId=37837&aId=D732E93E740897CD25C644489EB118BF http://ibiweb.org/do/viewdocument/DocumentDetail?linkId=37837&aId=D732E93E740897CD25C644489EB118BF http://www.pcmanet.org/assets/2008-03-25_Research_sp_trendsstrategies.pdf http://www.pcmanet.org/assets/2008-03-25_Research_sp_trendsstrategies.pdf http://www.walgreenshealth.com/common/pdf/FinalSOI05152007.pdf http://www.pcmanet.org/assets/2008-03-25_Research_sp_trendsstrategies.pdf http://www.walgreenshealth.com/common/pdf/FinalSOI05152007.pdf http://www.walgreenshealth.com/common/pdf/FinalSOI05152007.pdf http://www.regentatlantic.com/media/pdf/RegentAtlantic-Pharma-Paper-Dec-07.pdf http://www.regentatlantic.com/media/pdf/RegentAtlantic-Pharma-Paper-Dec-07.pdf http://www.regentatlantic.com/media/pdf/RegentAtlantic-Pharma-Paper-Dec-07.pdf http://www.regentatlantic.com/media/pdf/RegentAtlantic-Pharma-Paper-Dec-07.pdf http://online.wsj.com/public/article/SBI10076460147574133.html?mod=blog http://online.wsj.com/public/article/SBI10076460147574133.html?mod=blog http://online.wsj.com/public/article/SBI10076460147574133.html?mod=blog http://mcfpanelintelligence.com/view_pr.asp?file=may092006 http://mcfpanelintelligence.com/view_pr.asp?file=may092006 http://mcfpanelintelligence.com/view_pr.asp?file=may092006

Table of Contents Feed for the Digital Edition of Biotechnology Healthcare - July/August 2008

Biotechnology Healthcare - July/August 2008 Openers Contents Editorial/David B. Nash, MD, MBA Drug Track Health Plan Confidential Rheumatoid Arthritis A Decade of Trial, Error, False Starts, and Hope What Path Will Comparative Effectiveness Research Take? RA Therapies in Development: A New Generation of Relief Assessing the Full Impact of RA on Employers and Payers Stem Cells: Health Insurance You Can Bank On Specialty Pharmacy Employer to Employer Personalized Medicine Trends Clinical Briefs

Biotechnology Healthcare - July/August 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.